Combining conventional therapy with immunotherapy: A risky business?-Reference-Cited by-同舟云学术

Combining conventional therapy with immunotherapy: A risky business?

Published:2019-05 Issue: Volume:113 Page:41-44
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Coosemans A.^ORCID,Vankerckhoven A.,Baert T.,Boon L.,Ruts H.,Riva M.,Blagden S.,Delforge M.,Concin N.,Mirza M.R.,Ledermann J.A.^ORCID,du Bois A.^ORCID,Vergote I.

Funder

Olivia Fund

Amgen Chair for Therapeutic Advances in Ovarian Cancer

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference18 articles.

1. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion;Schreiber;Science,2011

2. The hallmarks of cancer: the next generation;Hanahan;Cell,2011

3. Cancer cell-intrinsic PD-1 and implications in combinatorial immunotherapy;Yao;Front Immunol,2018

4. Rapid progression of Adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy;Ratner;N Engl J Med,2018

5. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response;Jiang;Nat Med,2018

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of the efficacy and safety of anlotinib for the treatment of recurrent epithelial ovarian cancer;Discover Oncology;2024-08-29

2. TIM3 Checkpoint Inhibition Fails to Prolong Survival in Ovarian Cancer-Bearing Mice;Cancers;2024-03-14

3. Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies;Oncology and Therapy;2024-01-30

4. Enhanced chemoimmunotherapy of breast cancer in mice by apolipoprotein A1-modified doxorubicin liposomes combined with interleukin-21;Journal of Drug Targeting;2023-11-06

5. Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy;Frontiers in Immunology;2023-09-07